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Summary
Background.— Ischaemia-modiﬁed albumin (IMA) is a new sensitive diagnostic biochemical
marker of myocardial ischaemia. The purpose of the study was to analyse the prognostic value
of IMA in patients admitted for non-ST-segment elevation acute coronary syndromes (NSTE ACS).
Methods.— Consecutive patients admitted for NSTE ACS in our institution were prospectively
included. IMA, cardiac troponin I (TnI) and C-reactive protein (CRP) were measured in all
patients within 3 h of last chest pain. The clinical combined endpoint was major adverse car-
diac events (MACE) including cardiac death, nonfatal myocardial infarction (MI) and recurrent
ischaemia leading to urgent revascularization. The independent prognostic impact of IMA on
occurrence of the combined endpoint during hospitalization and at 1 year was tested by a logis-
tic regression model and was systematically adjusted for other known clinical and biological
predictors.
Results.— Seventy-nine patients were enrolled. Nine (11.4%) patients experienced the com-
bined endpoint during hospitalization and 16 (20.2%) during 1-year follow-up. Median IMA level
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p = 0.003).
Conclusion.— Baseline levels of IMA were associated with both short- and long-term cardiovas-
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p = 0,03) et à un an (HR : 1,07 ; 95 % IC : 1,03—1,12 ; p = 0,003).
Conclusion.— L’IMA est un facteur pronostique indépendant, de survenue d’ECM durant
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ackground
everal cardiac biomarkers, now routinely available to
linicians, have emerged as strong predictors of risk in
atients presenting with non-ST-elevation acute coronary
yndromes (NSTE ACS). Elevated levels of troponin I (TnI)
1], C-reactive protein (CRP) [2] and B-type natriuretic pep-
ide (BNP) [3,4] are associated with higher rates of death
nd recurrent ischaemic events after NSTE ACS. Several
ecent studies have shown that ischaemia-modiﬁed albu-
in (IMA), as measured by the albumin cobalt binding
ACB) test, can be a potential novel marker of transient
yocardial [5—7] or peripheral ischaemia [8]. The ACB
est measures the binding capacity of exogenous cobalt
o the N-terminus of human albumin. In the presence of
schaemia, structural changes take place in the N-terminus
f albumin that rapidly reduces its binding capacity for tran-
ition metal ions. Recent studies have shown that IMA is
ighly sensitive for identifying ACS, with a good negative
redictive value in patients with a normal electrocardio-
ram and negative troponin [6,7]. IMA has also been shown
o be elevated in patients after percutaneous coronary
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ntervention (PCI) as a result of periprocedural ischaemia
9—11]. However, the prognostic value of IMA has only been
ested in studies of patients with end-stage renal disease
12], presenting with chest pain [13] and after elective
CI [14], but no data are available about the prognos-
ic value of IMA after NSTE ACS. We therefore designed
prospective study to assess the additional prognostic
alue of IMA over conventional clinical and biochemical
arkers of cardiovascular (CV) risk in patients with NSTE
CS.
ethods
atient population
onsecutive patients admitted for NSTE ACS within 3 h ofL. Bali et al.
was signiﬁcantly higher in patients with MACE during hospitalization (115 [93—126] U/mL ver-
sus 100 [42—138] U/mL; p = 0.007) and at 1 year (114 [93—126] U/mL versus 97 [42—138] U/mL;
p < 0.001). After adjustment for conventional prognostic risk factors, IMA remained an inde-
pendent predictor of MACE both during hospitalization (odds ratio [OR]: 1.08; 95% conﬁdence
interval [CI]: 1.01—1.16; p = 0.03) and at 1 year (hazards ratio [HR]: 1.07; 95% CI: 1.03—1.12;cular (CV) events in patients admitted for NSTE ACS.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Objectif.— L’albumine modiﬁée par l’ischémie (IMA) est un biomarqueur diagnostique précoce
de l’ischémie myocardique. Notre étude avait pour objectif d’évaluer la valeur pronostique de
l’IMA chez les patients hospitalisés pour syndrome coronaire aigu sans sur décalage du segment
ST (SCA ST—).
Matériel et méthodes.— Des patients consécutifs hospitalisés dans notre service d’urgence
coronaire pour SCA ST— ont été prospectivement inclus. L’IMA, la CRP et la troponine I (cTnI) ont
été dosées chez tous les patients dans un délai de trois heures maximum après la dernière scène
clinique ischémique. L’IMA a été mesurée par spectrophotométrie en utilisant la technique
albumin cobalt binding (ACB) test . Le critère d’évaluation était la survenue d’événements car-
diovasculaires majeurs (ECM) associant décès d’origine cardiovasculaire, récidive d’infarctus du
myocarde non fatals ou nouvelles angioplasties pour récidive angineuse durant l’hospitalisation
et à un an. L’impact pronostique de l’IMA a été examiné par régression logistique et les résul-
tats ont été systématiquement ajustés aux autres facteurs prédictifs biologiques et cliniques
connus.
Résultats.— Soixante-dix-neuf patients ont été inclus. Neuf patients (11,4 %) ont présenté des
ECM durant la période intrahospitalière et 16 (21,3 %) à un an. Les valeurs médianes de l’IMA
étaient signiﬁcativement plus élevées dans le groupe de patients ayant présenté des ECM durant
l’hospitalisation (115U/mL [93—126] versus 100U/mL [42—138] ; p = 0,007) et à un an (médi-
ane IMA : 113,50UI/mL [93—126] versus 97UI/mL [42—138] ; p < 0,001). Après ajustement aux
autres facteurs pronostiques cliniques et biologiques classiques, l’IMA restait un facteur pronos-
tique indépendant de survenue d’ECM durant l’hospitalisation (OR : 1,08 ; 95 % IC : 1,01—1,16 ;ast chest pain between June 2006 and December 2006 were
ligible for this prospective study. Patients were required
o have crescendo, prolonged (≥ 20min) or recurrent
≥ two episodes lasting at least 5min) anginal pain at
est or with minimal effort within the prior 24 h that was
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accompanied by objective evidence of ischaemic heart
disease. The latter consisted of electrocardiographic (ECG)
changes (ST depressions greater than or equal to 0.05mV,
transient ST elevations greater than or equal to 0.10mV
or T-wave inversions greater than or equal to 0.3mV in at
least two leads), elevated cardiac biomarkers of necrosis
or a documented history of coronary artery disease. The
exclusion criteria were age below 18 years, persistent
ST-segment elevation acute coronary syndrome (ACS), New
York Heart Association class IV, coronary artery bypass graft
(CABG) surgery within the previous 3months, creatinine
clearance below 30mL/min, total serum albumin extremely
low (< 30 g/L) or extremely high (> 55 g/L), patient samples
that appeared grossly lipaemic or icteric, severe peripheral
or cerebral vascular disease or refusal of the patients to
participate. Patients were treated according to current
guidelines [15—17]. The initial strategy was either invasive
(PCI) or medical (including patients with a culprit lesion not
suitable for PCI after coronary angiography).
Clinical data
Clinical data were collected on admission including history
of coronary artery disease (deﬁned as previous CABG or
PCI), diabetes mellitus, ECG changes (as deﬁned above) and
ejection fraction (by echocardiography). All patients had
baseline blood samples collected on admission and within
3 h of the last ischaemic episode.
Measurement of biochemical markers
Blood samples for testing cardiac biomarkers (TnI, CRP and
IMA) were drawn in the coronary care unit. TnI was measured
using the ADVIA centaur® TnI (Siemens medical solution
diagnostics SAS, 95613 Cergy-Pontoise cedex, France, cut-
off value: 0.3 ng/mL). CRP was measured on a Synchron® LX
20 analyzer (Beckman Coulter, 95942 Villepinte—Roissy-CDG,
France). IMA was evaluated as described previously [18].
Brieﬂy, the ACB test is a quantitative in vitro diagnostic test
that detects IMA by measuring the cobalt binding capacity
of albumin in human serum (Ischemia Technologies, Den-
ver, CO). Human serum, including that collected in serum
separator tubes, is the only specimen type for the ACB-test
measurement for IMA and was performed on a Synchron®
LX 20 analyzer (Beckman Coulter, Villepinte, France). The
test sample and a ﬁxed amount of cobalt in the form of
cobalt chloride were incubated. Dithiothreitol was added to
react with the cobalt not bound to the N-terminus to form a
measurable colour. The absorbance was measured by spec-
trophotometer. IMA values were determined in a population
of 49 healthy subjects (equal numbers of men and women,
age range: 25—65 years). Results for IMA in the healthy pop-
ulation showed a normal distribution (mean: 88± 8U/mL;
median: 89U/mL). The parametric and nonparametric upper
95th percentile was 99U/mL. The initial strategy (invasive
by PCI or medical) was deﬁned according to current guide-
lines.Clinical endpoints
The clinical endpoint was a combination of major adverse
cardiovascular events (MACE) occurring after the initial
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trategy (invasive or medical) including: CV death, nonfatal
yocardial infarction (MI) and recurrent ischaemia lead-
ng to urgent revascularization. CV death was deﬁned as
ny death without evidence of noncardiac origin. Nonfa-
al MI was deﬁned as periprocedural elevation of creatine
inase (CK)-MB above 3N (N < 100U/mL) or any elevation
f CK-MB or troponin above normal, following new onset
f ischaemic symptoms during follow-up. Late events were
ssessed prospectively by clinical visit or at least phone
nterview with recovery of the ﬁle and angiography if the
atient had been admitted to another institution. The
reating physician and the investigators who evaluated the
linical endpoints were blinded to the results of the cardiac
iomarkers.
tatistical analysis
tatistical analysis was performed using the SPSS software
version 13.0 2004 SPSS Inc, Chicago, Illinois, USA). Con-
inuous variables are expressed as medians and ranges.
ategorical variables are expressed as frequencies and per-
entages. Comparisons between the groups were made
ith the Chi-square or Fisher’s exact test for categori-
al variables and mean levels were compared using the
ann—Whitney test for continuous variables. The effects of
iological factors on in-hospital CV events were examined by
logistic regression model. Follow-up of individual patients
as restricted to 1 year after diagnosis, at which time the
atients were censored if still free of MACE. The overall
isease-free survival was estimated by the Kaplan—Meier
ethod. Then a Cox proportional hazards model was used
o calculate the hazards ratio (HR) and its 95% conﬁdence
nterval (CI) associated with MACE. The proportional haz-
rds assumption was assessed using Schoenfeld residuals.
he independent prognostic impact of IMA on occurrence of
he combined endpoint both during hospitalization and at
year was systematically adjusted for other known clinical
nd biological predictors. The C-index was used to assess the
redictive value of the Cox model. All statistical tests were
wo-sided and p values below 0.05 were considered statisti-
ally signiﬁcant. To assess the best predictive value of IMA,
eceiver operating characteristic (ROC) curves were gener-
ted, and the area under the curves (AUC) was calculated.
ptimal discrimination limits were identiﬁed at the cut point
hat maximizes sensitivity and speciﬁcity to predict hospi-
al and 1-year outcomes. The sensitivity and speciﬁcity for
roup distinction were determined according to sensitivity,
.e.: true positives/(true positives + false negative)× 100%
nd speciﬁcity, i.e.: (true negatives/(true negatives + false
ositives)× 100%).
esults
total of 79 patients with NSTE ACS who fulﬁlled the
nrolment criteria were included in our study. Demo-
raphic data are summarized in Table 1. The mean age
as 68.8± 14 years and 73.4% were men. Fifty-three (67%)
atients had signiﬁcant ECG changes. Sixteen (20.2%)
atients presented with troponin elevation at admission
bove the cut-off deﬁned by the laboratory, with a median
alue of 0.03 ng/mL (range: 0—32.4). The median value for
648 L. Bali et al.
Table 1 Clinical characteristics of the population.
Characteristic N = 79
Men, N (%) 58 (73.4)
Women, N (%) 21 (26.6)
Age (years)a 64.8± 14
History of revascularization (CABG or
PCI), N (%)
36 (45.5)
Previous CABG, N (%) 10 (12.7)
Previous PCI, N (%) 26 (32.9)
Diabetes mellitus, N (%) 19 (24.1)
Current smoker, N (%) 46 (58.2)
Hypertension, N (%) 60 (75.9)
Family history of CAD, N (%) 9 (11.4)
Dyslipidaemia, N (%) 55 (69.6)
Body mass index (kg/m2)a 25.6± 2.9
ECG changes: ST depression or T-wave
inversion, N (%)
53 (67)
Troponin I (ng/mL)b 0.03 (0—32.4)
Positive troponin at admission
(> 0.3 ng/mL), N (%)
16 (20.2)
C-reactive protein (mg/L)b 10 (1—159)
Ischaemia modiﬁed albumin (U/mL)b 102 (42—138)
Glycoprotein IIb/IIIa antagonists, N (%) 21 (26.6)
Initial invasive strategy, N (%) 33 (41.7)
Ejection fraction≤ 40%, N (%) 11 (14)
Ejection fraction (%)a 49.6± 8
CABG: coronary artery bypass graft; CAD: coronary artery dis-
ease; ECG: elecrocardiographic; PCI: percutaneous coronary
intervention.
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Table 3 Predictors of in-hospital major adverse cardio-
vascular events (MACE): multivariable analysis.
Factor Odds
ratio
95% conﬁdence
interval
p
C-reactive proteina 1.00 0.97—1.04 0.81
Troponin Ia 1.06 0.93—1.22 0.34
Agea 1.07 0.98—1.18 0.12
Female sex 1.53 0.14—17.28 0.73
Diabetes mellitus 1.90 0.16—22.82 0.61
Ejection fractiona 0.90 0.81—1.01 0.06
Invasive strategy (PCI) 0.47 0.06—3.71 0.47
a Continuous variables.
Figure 1. Major adverse cardiovascular event (MACE)-free sur-
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MMean± standard deviation.
b Median (range).
RP was 10mg/L (range: 1—159). Results for IMA analysis
howed a normal distribution from 42 to 138U/mL, with a
edian value of 102U/mL (mean: 100± 18).
redictors of in-hospital events
uring hospitalization, nine (11.4%) MACE occurred, includ-
ng two CV deaths, ﬁve nonfatal MI (including one failed
CI and one acute stent thrombosis) and two recurrent
schaemias leading to urgent revascularization (one after
revious PCI on another segment and one after the initial
edical strategy). Median IMA and TnI values were signif-
cantly higher in patients with MACE during hospitalization
Table 2). There was no statistically signiﬁcant difference in
edian CRP in patients with MACE (Table 2). After adjust-
ent for clinical characteristics (age, sex, diabetes mellitus
nd left ventricular ejection fraction), biological data (CRP
nd TnI) and initial strategy (invasive or medical), IMA
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Table 2 Predictors of in-hospital major adverse cardiovascula
Biomarkers, median (range) MACE
Ischaemia-modiﬁed albumin (U/mL) 115 (93—126
Troponin I (ng/mL) 1.13 (0.03—
C-reactive protein (mg/L) 12 (5—159)ival during the ﬁrst year after diagnosis according to initial value of
schaemia modiﬁed albumin (cut-off: 109). IMA: ischaemia-modiﬁed
lbumin.
emained an independent predictor of MACE during hospi-
alization (Table 3).
redictors of 1-year follow-up
ACE reported at 1 year included in-hospital events. Sixteen
20.2%) MACE were reported, including four (5%) CV deaths,
ight (10.1%) nonfatal MI and four (5%) recurrent ischaemias
eading to urgent revascularization. IMA level was signiﬁ-
antly higher in patients with MACE, as was TnI and CRP
Table 4).
r events (MACE): univariate analysis.
No MACE p
) 100 (42—138) 0.007
32.4) 0.03 (0.03—25.8) 0.01
10 (1—60) 0.18
Ischaemia-modiﬁed albumin and non-ST-segment elevation acute coronary syndromes 649
Table 4 Predictors of 1-year follow-up major adverse cardiovascular events (MACE): univariate analysis.
Biomarker, median (range) MACE No MACE p
Ischaemia-modiﬁed albumin (U/mL) 114 (93—126) 97 (42—138) < 0.001
32.4) 0.03 (0.03—25.81) 0.015
9 (1—60) 0.015
Figure 2. Receiver operating characteristic curve for determina-
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sTroponin I (ng/mL) 0.33 (0.03—
C-reactive protein (mg/L) 12 (5—159)
Fig. 1 shows MACE-free survival during the ﬁrst year after
diagnosis. After adjustment for clinical characteristics (age,
sex, diabetes mellitus and left ventricular ejection frac-
tion), biological data (CRP and TnI) and initial treatment
strategy (invasive or medical), IMA remained an indepen-
dent predictor of MACE at 1 year as was ejection fraction
(Table 5). The prognostic accuracy of this Cox model was
relatively good (C-index: 0.82). There was no correlation
between different biomarkers (maximal indict between CRP,
cTnI and IMA: 0.23).
Determination of predictive cut-off value of
IMA for 1-year prognosis
Using ROC analysis we determined the most predictive
value of IMA for 1-year prognosis. The cut-off was found
to be 109U/mL (area under ROC curve: 0.79), predict-
ing MACE with positive and negative predictive values of
44.4 and 91.7%, respectively (odds ratio [OR]: 8.8; CI 95%:
2.46—31.48) (Fig. 2). Fifty (63.3%) patients had an IMA
value below 109U/mL with four (8%) events, and 29 (36.7%)
patients had an IMA value greater than or equal to 109U/mL
with 12 events (41.4%) (OR: 8.8; CI 95%: 2.46—31.48;
p = 0.008) (Fig. 3).
Discussion
This study showed the potential in-hospital and 1-year
prognostic value of IMA in patients with NSTE ACS. In
multivariable analysis, we demonstrated that IMA is an
independent predictor of in-hospital and 1-year follow-up
events. In addition, we have demonstrated that a cut-off
value of 109U/mL might be a reliable threshold to predict
increased risk of events in patients with NSTE ACS.
CV disease is the principal cause of mortality in industri-
alized countries [16,17,19,20]. It is responsible, each year,
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Table 5 Predictors of 1-year follow-up major adverse cardiov
Factors Hazard ratio
Ischaemia-modiﬁed albumin (U/mL)a 1.07
C-reactive protein (mg/L)a 0.99
Troponin I (ng/mL)a 1.02
Agea 1.05
Female sex 2.37
Diabetes mellitus 1.65
Ejection fractiona 0.91
Invasive strategy (PCI) 0.97
C-index: 0.82.
a Continuous variables.ion of most relevant cut-off of ischaemia-modiﬁed albumin (IMA)
or prognosis. CI: conﬁdence interval; NPV: negative predictive
alue; OR: odds ratio; PPV: positive predictive value; Se: sensitivity;
p: speciﬁcity.
or 100,000 deaths in Europe [19,20] and 500,000 deaths
n the United States [16,21,22]. According to the European
ociety of Cardiology guidelines, markers indicating a high-
isk patient include recurrent ischaemia, recurrent chest
ain, elevated troponin levels, diabetes mellitus, haemo-
ynamic instability, early postinfarction unstable angina
nd dynamic ST-segment changes (ST-segment depression
r transient segment elevation) [16,17]. Biomarkers of MI
TnI, CK), systemic inﬂammation (CRP) and haemodynamic
tress (BNP and NTproBNP) have already been shown to be
ccurate prognostic markers in NSTE ACS [1—4]. It is cur-
ently standard that patients presenting with chest pain
o an emergency department (ED) are evaluated not only
y ECG but also by determination of cardiac biomarkers of
yonecrosis, including CK and TnI. However, these markers
ascular events (MACE) in multivariable analysis.
95% conﬁdence interval p
1.03—1.12 0.003
0.98—1.02 0.95
0.95—1.09 0.55
0.99—1.10 0.08
0.47—12.05 0.30
0.36—7.54 0.52
0.86—0.97 0.004
0.31—3.04 0.96
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Rigure 3. Incidence of major adverse cardiovascular events
MACE) according to initial value of ischaemia-modiﬁed albumin
IMA) (cut-off: 109).
re not helpful in detecting myocardial ischaemia occurring
ithout myonecrosis. Additionally, a relatively long time
lapses before these markers increase in concentration.
ence, novel early markers of ACS are required.
IMA is an early marker of myocardial ischaemia, with
iagnostic value for ischaemia related to vascular disease
5—8] or to PCI [9—11]. In previous studies, IMA has been
hown to have a good negative predictive value for exclud-
ng ACS in patients presenting to the EDwith chest pain [6,7].
owever, its prognostic value has not yet been well estab-
ished. In a prospective observational study of 114 patients
n end-stage renal disease, Sharma et al. [12] demonstrated
he predictive prognostic value of baseline IMA greater than
5U/mL on mortality in 84 patients, with a mean follow-
p of 2.25± 0.71 years. Worster et al. [13] evaluated the
ccurrence of ischaemic CV events within the 72 h follow-
ng admission, and showed that IMA measured within 6 h
fter last chest pain was a poor predictor of MACE. However,
his study included a low risk and heterogeneous popula-
ion and assessed the prognostic value of IMA on a sample
aken within 6 h after the last episode of chest pain, which
s late when taking into account the fast return to nor-
al of IMA after its increase during ischaemia. Dusek et al.
14], in a population of 60 patients undergoing elective PCI,
eported an association between post-PCI IMA elevation and
igher rate of target lesion revascularization during a long
ollow-up period. These data have suggested a potential
rognostic value of IMA in coronary artery disease. How-
ver, to our knowledge, no previous study has investigated
he prognostic value of IMA, focusing on patients with NSTE
CS.
In the present study, we demonstrated the independent
rognostic value of IMA on top of conventional markers (TnI,
RP) for NSTE ACS patients. IMA appears not only as a diag-
ostic marker of ischaemic events but also an indicator
f the severity of ischaemia with prognostic implications.
ndeed, the predictive value on prognosis of IMA during an
CS could be linked with its capacity to detect the severity
f ischaemia, related to both short- and long-term prog-
osis. Current guidelines [16,17] propose to individualize
herapy for NSTE ACS patients based on prognostic markers
uch as troponin. However, detection of high-risk NSTE ACS
atients who may beneﬁt from optimized timing of percuta-L. Bali et al.
eous coronary angioplasty and/or antithrombotic therapy
emains difﬁcult. The additive value of IMA could be help-
ul in identifying these patients. The pathophysiology of ACS
s complex; therefore, it is unlikely that a single biomarker
ould evaluate global CV risk. Thus, it is of interest to pro-
ose that multimarker scores using several biomarkers could
otentially be used to predict CV risk and patient progno-
is. Several studies support the concept of a multimarker
trategy for risk stratiﬁcation in patients with ACS [23,24].
MA, with its excellent negative predictive value, could be
ntegrated into a risk score associated with TnI, BNP and
RP [25]. In addition, IMA could be used in primary pre-
ention to detect asymptomatic ischaemia and/or hypoxic
tress in high-risk CV patients. The potential mechanisms
esponsible for the strong association between IMA eleva-
ions and short- and long-term major CV events cannot be
scertained in the present study. IMA is a sensitive but unspe-
iﬁc marker of myocardial ischaemia, whose level is also
levated in nonmyocardial ischaemia. Thus, IMA —–like car-
iac TnI—– should be integrated with the clinical context for
rognostic assessment.
tudy limitations
he main limitations of our study were the small sample size
nd occurrence of events. The results should be conﬁrmed
n larger studies. Nevertheless, the baseline characteristics
f the population correspond to epidemiological registries
ublished on NSTE ACS [19—22] and the prognostic value
f TnI and CRP [1,2,25]. Moreover, additional research is
equired to understand the physiopathological link between
levated levels of IMA and increased risk of MACE in patients
ith NSTE ACS.
onclusions
n this study, baseline IMA level was associated with both
hort- and long-term recurrent ischaemic events in patients
dmitted to hospital for NSTE ACS. In addition, a cut-off
f 109U/mL had a good predictive negative value, which
s potentially usable in daily clinical practice. These data
uggest that IMA —–a diagnostic biochemical marker of NSTE
CS—– is also of prognostic value in this clinical setting.
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